Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

Elucidating Biosimilars Characterization

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.
Oct 2, 2013

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.

Novel Solvent-Free Method to Manufacture Metastable Drug Forms

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.
Sep 30, 2013

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.

Roche's Timesaving Formulation for Breast Cancer Drug Approved in Europe

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.
Sep 2, 2013

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.

Gauging the Outlook of the Biologics Market

A Q&A with Mike Jenkins, Catalent
Sep 2, 2013

Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.

The Importance of Characterization in Biosimilars Development

Industry experts discuss the requirements and challenges involved in getting a biosimilar product from bench to launch.
Sep 2, 2013

Industry experts discuss the requirements and challenges involved in getting a biosimilar product from bench to launch.

Novartis' MS Drug Gilenya Under FDA Investigation for PML Case

FDA has issued a safety alert after a patient with multiple sclerosis (MS) in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) following treatment with Gilenya (fingolimod).
Sep 2, 2013

FDA has issued a safety alert after a patient with multiple sclerosis in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy following treatment with Gilenya (fingolimod).

MHRA Warns of Dangerous Traditional Chinese Medicines

The MHRA has issued a warning to the public not to use unlicensed traditional Chinese medicines after discovering that some of them contain dangerously high levels of lead, mercury and arsenic.
Aug 22, 2013

The MHRA has issued a warning to the public not to use unlicensed traditional Chinese medicines after discovering that some of them contain dangerously high levels of lead, mercury and arsenic.

ABPI Sets Guidelines on Clinical Trial Disclosure

ABPI toolkit provides guidance to pharmaceutical companies on how to meet clinical trial transparency requirements
Aug 16, 2013

ABPI toolkit provides guidance to pharmaceutical companies on how to meet clinical trial transparency requirements

Rx-360 Advances Supply-Chain Security

Rx-360, a pharmaceutical industry supply-chain consortium, is advancing approaches between pharmaceutical companies, suppliers, and contract manufacturers to better secure the pharmaceutical supply chain.
Aug 1, 2013

Rx-360, a pharmaceutical industry supply-chain consortium, is advancing approaches between pharmaceutical companies, suppliers, and contract manufacturers to better secure the pharmaceutical supply chain.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here